Search Results for: PDGFRA

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
NF2 NF2, moesin-ezrin-radixin like (MERLIN) tumor suppressor
  • Regulation of actin dynamics for phagocytic cup formation
  • RHO GTPases activate PAKs
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
  • Malignant pleural mesothelioma
NHERF1 NHERF family PDZ scaffold protein 1
  • Nephrolithiasis/osteoporosis, hypophosphatemic
PDGFA platelet derived growth factor subunit A
  • Non-integrin membrane-ECM interactions
  • NFE2L2 regulating tumorigenic genes
  • Glioma
  • Malignant pleural mesothelioma
PDGFB platelet derived growth factor subunit B
  • Platelet degranulation
  • PIP3 activates AKT signaling
  • Downstream signal transduction
  • Signaling by PDGF
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Non-integrin membrane-ECM interactions
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Pegpleranib
  • Glioma
  • Malignant pleural mesothelioma
PDGFC platelet derived growth factor C
PDGFRB platelet derived growth factor receptor beta
  • PIP3 activates AKT signaling
  • Downstream signal transduction
  • Signaling by PDGF
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Becaplermin
  • Sorafenib
  • Imatinib
  • Dasatinib
  • Sunitinib
  • XL999
  • XL820
  • Pazopanib
  • Midostaurin
  • Regorafenib
  • Nintedanib
  • Polaprezinc
  • Trapidil
  • Foreskin fibroblast (neonatal)
  • Tivozanib
  • Fostamatinib
  • Erdafitinib
  • Pexidartinib
  • Ripretinib
  • Pralsetinib
  • Glioma
PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha
  • PI3K Cascade
  • IRS-mediated signalling
  • GPVI-mediated activation cascade
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K events in ERBB4 signaling
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Synthesis of PIPs at the plasma membrane
  • GAB1 signalosome
  • Signaling by cytosolic FGFR1 fusion mutants
  • Downstream signal transduction
  • PI3K events in ERBB2 signaling
  • PI3K/AKT activation
  • Signaling by ALK
  • Downstream TCR signaling
  • Role of phospholipids in phagocytosis
  • Tie2 Signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Nephrin family interactions
  • CD28 dependent PI3K/Akt signaling
  • G alpha (q) signalling events
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Constitutive Signaling by EGFRvIII
  • PI-3K cascade:FGFR1
  • PI-3K cascade:FGFR2
  • PI-3K cascade:FGFR3
  • PI-3K cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • Signaling by FGFR3 in disease
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates PI3K/AKT signaling
  • RET signaling
  • Extra-nuclear estrogen signaling
  • RAC1 GTPase cycle
  • RAC2 GTPase cycle
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Activated NTRK2 signals through PI3K
  • Interleukin receptor SHC signaling
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • Activated NTRK3 signals through PI3K
  • FLT3 Signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Signaling by CSF1 (M-CSF) in myeloid cells
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Signaling by LTK in cancer
  • Signaling by LTK
  • High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
  • Co-stimulation by ICOS
  • ATP
  • Caffeine
  • XL765
  • Wortmannin
  • Pilaralisib
  • Alpelisib
  • Copanlisib
  • Ovarian cancer
PIK3R1 phosphoinositide-3-kinase regulatory subunit 1
  • PI3K Cascade
  • IRS-mediated signalling
  • GPVI-mediated activation cascade
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K events in ERBB4 signaling
  • PIP3 activates AKT signaling
  • Interleukin-7 signaling
  • Interleukin-7 signaling
  • Signaling by SCF-KIT
  • Synthesis of PIPs at the plasma membrane
  • GAB1 signalosome
  • Signaling by cytosolic FGFR1 fusion mutants
  • Downstream signal transduction
  • PI3K events in ERBB2 signaling
  • PI3K/AKT activation
  • Signaling by ALK
  • Downstream TCR signaling
  • Role of phospholipids in phagocytosis
  • Tie2 Signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Nephrin family interactions
  • CD28 dependent PI3K/Akt signaling
  • G alpha (q) signalling events
  • GP1b-IX-V activation signalling
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Constitutive Signaling by EGFRvIII
  • PI-3K cascade:FGFR1
  • PI-3K cascade:FGFR2
  • PI-3K cascade:FGFR3
  • PI-3K cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • Signaling by FGFR3 in disease
  • RAF/MAP kinase cascade
  • Interleukin-4 and Interleukin-13 signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates PI3K/AKT signaling
  • RET signaling
  • RHOA GTPase cycle
  • Extra-nuclear estrogen signaling
  • RHOB GTPase cycle
  • RHOC GTPase cycle
  • CDC42 GTPase cycle
  • RAC1 GTPase cycle
  • RAC2 GTPase cycle
  • RHOD GTPase cycle
  • RHOG GTPase cycle
  • RHOJ GTPase cycle
  • RHOU GTPase cycle
  • RAC3 GTPase cycle
  • RHOV GTPase cycle
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Activated NTRK2 signals through PI3K
  • RHOF GTPase cycle
  • Interleukin receptor SHC signaling
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • Activated NTRK3 signals through PI3K
  • FLT3 Signaling
  • FLT3 Signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Signaling by CSF1 (M-CSF) in myeloid cells
  • RND3 GTPase cycle
  • RND2 GTPase cycle
  • RND1 GTPase cycle
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by ALK fusions and activated point mutants
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Signaling by LTK in cancer
  • Signaling by LTK
  • Co-stimulation by ICOS
  • SF1126
  • Enzastaurin
  • Wortmannin
PLCG1 phospholipase C gamma 1
  • ISG15 antiviral mechanism
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PLCG1 events in ERBB2 signaling
  • DAG and IP3 signaling
  • PLC-gamma1 signalling
  • Synthesis of IP3 and IP4 in the cytosol
  • Downstream signal transduction
  • Signaling by ALK
  • Generation of second messenger molecules
  • Role of phospholipids in phagocytosis
  • Role of phospholipids in phagocytosis
  • PECAM1 interactions
  • EGFR interacts with phospholipase C-gamma
  • DAP12 signaling
  • FCERI mediated MAPK activation
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • Role of second messengers in netrin-1 signaling
  • VEGFR2 mediated cell proliferation
  • VEGFR2 mediated cell proliferation
  • Constitutive Signaling by EGFRvIII
  • Phospholipase C-mediated cascade: FGFR1
  • Phospholipase C-mediated cascade; FGFR2
  • Phospholipase C-mediated cascade; FGFR3
  • Phospholipase C-mediated cascade; FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • Signaling by FGFR3 in disease
  • RET signaling
  • Activated NTRK2 signals through PLCG1
  • Activated NTRK2 signals through PLCG1
  • Erythropoietin activates Phospholipase C gamma (PLCG)
  • Activated NTRK3 signals through PLCG1
  • Activated NTRK3 signals through PLCG1
  • FCGR3A-mediated IL10 synthesis
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Signaling by ALK fusions and activated point mutants
PLPP6 phospholipid phosphatase 6
  • Cholesterol biosynthesis
PRMT5 protein arginine methyltransferase 5
  • snRNP Assembly
  • RMTs methylate histone arginines
  • Regulation of TP53 Activity through Methylation
PTPN11 protein tyrosine phosphatase non-receptor type 11
  • Interleukin-6 signaling
  • PI3K Cascade
  • MAPK3 (ERK1) activation
  • MAPK1 (ERK2) activation
  • GPVI-mediated activation cascade
  • Prolactin receptor signaling
  • PIP3 activates AKT signaling
  • Spry regulation of FGF signaling
  • Signaling by SCF-KIT
  • GAB1 signalosome
  • Downstream signal transduction
  • PECAM1 interactions
  • Tie2 Signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Signaling by Leptin
  • Co-inhibition by CTLA4
  • Co-inhibition by PD-1
  • Signal regulatory protein family interactions
  • Netrin mediated repulsion signals
  • Platelet sensitization by LDL
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • FRS-mediated FGFR3 signaling
  • PI-3K cascade:FGFR3
  • FRS-mediated FGFR4 signaling
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Regulation of IFNG signaling
  • RET signaling
  • Interleukin-20 family signaling
  • MET activates PTPN11
  • Regulation of RUNX1 Expression and Activity
  • Interleukin-37 signaling
  • Activated NTRK2 signals through FRS2 and FRS3
  • Interferon alpha/beta signaling
  • Regulation of IFNA/IFNB signaling
  • Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE)
  • FLT3 Signaling
  • STAT5 Activation
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF1 (M-CSF) in myeloid cells
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • SARS-CoV-2 activates/modulates innate and adaptive immune responses
  • Co-inhibition by BTLA
  • Dodecyltrimethylammonium
  • Metachondromatosis
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
RAF1 Raf-1 proto-oncogene, serine/threonine kinase
  • Stimuli-sensing channels
  • Rap1 signalling
  • GP1b-IX-V activation signalling
  • CD209 (DC-SIGN) signaling
  • RAF activation
  • MAP2K and MAPK activation
  • Negative feedback regulation of MAPK pathway
  • Negative regulation of MAPK pathway
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF1 fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • SHOC2 M1731 mutant abolishes MRAS complex function
  • Gain-of-function MRAS complexes activate RAF signaling
  • IFNG signaling activates MAPKs
  • Sorafenib
  • LErafAON
  • XL281
  • iCo-007
  • Cholecystokinin
  • Regorafenib
  • Dabrafenib
  • Fostamatinib
RAPGEF1 Rap guanine nucleotide exchange factor 1
  • Frs2-mediated activation
  • Frs2-mediated activation
  • Downstream signal transduction
  • MET activates RAP1 and RAC1
  • RAC3 GTPase cycle
  • Erythropoietin activates RAS
  • Erythropoietin activates RAS
  • Regulation of signaling by CBL
SHB SH2 domain containing adaptor protein B
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
SHF Src homology 2 domain containing F
SMURF1 SMAD specific E3 ubiquitin protein ligase 1
  • Signaling by BMP
  • Downregulation of TGF-beta receptor signaling
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • Asymmetric localization of PCP proteins
  • Hedgehog 'on' state
  • Hedgehog 'on' state
  • Regulation of RUNX2 expression and activity
  • Regulation of RUNX2 expression and activity
  • Regulation of RUNX3 expression and activity
  • Antigen processing: Ubiquitination & Proteasome degradation
SNX2 sorting nexin 2
  • Golgi Associated Vesicle Biogenesis
SNX4 sorting nexin 4
SNX6 sorting nexin 6

Page 6 out of 7 pages